Drug Trial Radar · NCT00300469
Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood
Last checked: Nov 20, 2026Latest source record: Jun 3, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
613
Actual
Start
Mar 2006
Primary completion
Feb 2007
Sponsor
- Lead sponsor
- AbbottIndustry
- Sponsor type
- Industry
- First posted
- Mar 9, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the safety and efficacy of fenofibric acid (ABT-335) + atorvastatin combination therapy with ABT-335 and atorvastatin monotherapy in subjects with multiple abnormal lipid levels in the blood.
Conditions
- Mixed Dyslipidemia
- Coronary Heart Disease
- Dyslipidemia
Interventions
ABT-335Drug
135 mg, daily, 12 weeks
AtorvastatinDrug
Daily, 12 weeks, see Arm Description for dosage information
PlaceboDrug
daily, 12 weeks, see Arm Description for placebo information
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Percent Change in Triglycerides From Baseline to Final VisitTime frame: Baseline to 12 Weeks (Final Visit)
- Mean Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Final VisitTime frame: Baseline to 12 Weeks (Final Visit)
- Mean Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Final VisitTime frame: Baseline to 12 Weeks (Final Visit)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Global Medical Information
North Chicago, Illinois
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.